

Manufactured in Poland for a healthier tomorrow

Generic medicines | Contract manufacturing | Research & development





200 YEARS OF POLISH PHARMACY

As Poland's oldest pharmaceutical company, TZF Polfa has played a pioneering role in building the country's pharmaceutical industry, breaking new ground in antibiotic production.

It was here in Tarchomin that Poland's first penicillin was produced in 1948, followed by the launch of insulin production in 1953. Today, we continue this mission by building on our rich heritage while constantly evolving to ensure that patients have access to safe and effective therapies.



Scan the code
to watch the video

The history of Polish pharmacy at Tarchomin

1823

The Chemical Products Factory is established in Warsaw, laying the foundations for what would later become Polfa.

1948

The first 4 grams of Polish penicillin are produced. Two years later, industrial-scale production begins.

1953

Polfa manufactures its first batch of insulin.

1958

Polfa expands into antibiotic production.

1961

Tetracycline is added to Polfa's product portfolio.

1962

Erythromycin production begins. Polfa becomes Poland's leading antibiotic manufacturer.







MEDICINE SUPPLY SECURITY

A State Treasury company producing pharmaceuticals: a public mission driven by business efficiency.

We take a systemic approach. While many countries are only beginning to consider how to strengthen the security of medicine supply, Poland already possesses a globally unique asset: the ability to manufacture pharmaceuticals through a state-controlled enterprise, irrespective of geopolitical or market pressures.

Local content – industrial independence and economic resilience

The company's activities focus on strengthening domestic manufacturing capabilities that support:

- pharmaceutical independence
- stable medicine supplies
- safe and reliable operation of the healthcare system



20 of the 32 EU critical list medicines produced in Poland are manufactured by TZF Polfa.

TZF POLFA – a strategic partnership



Capacity to co-create national intervention reserves



Agility for rapid production line changeovers



Readiness for swift deliveries



CONTRACT MANUFACTURING (CMO/CDMO)

We offer contract manufacturing services for medicinal products under two models: Contract Development and Manufacturing Organization (CDMO) services, which cover the development and manufacture of medicinal products on behalf of the client, and Contract Manufacturing Organization (CMO) services for products that have already been developed and registered. Our end-to-end service encompasses raw material, packaging material, and finished product procurement and quality control, alongside manufacturing, packaging, warehousing, and release to the market. The company operates modern manufacturing facilities equipped to produce the dosage forms detailed below.



130
dosage forms and strengths



25 million
packs produced annually



① Sterile pharmaceutical dosage forms:

- Powders for suspension or solutions for injection/infusion (vials)
- Lyophilized powders for solution or suspension for injection/infusion (vials)
- Solutions and suspensions for injection (vials, ampules, insulin cartridges)
- Highly potent injectable lyophilized powders (vials)
- Highly potent sterile injectable solutions (vials, prefilled syringes)

② Non-sterile pharmaceutical dosage forms:

- Uncoated, film-coated and sugar-coated tablets (blisters, containers)
- Hard gelatin capsules (blisters, containers)
- Powders and granules for oral suspension (bottles)
- Pressurized aerosols
- Gels, ointments (tubes)

③ Other services:

- Contract pharmaceutical product development
- Synthesis, isolation, and purification of active pharmaceutical ingredients (APIs)
- Micronization
- Quality control of medicinal products
- Manufacturing in compliance with EU GMP standards



TZF POLFA PORTFOLIO

We combine many years of experience in manufacturing generic medicines with the development of modern therapies, including highly potent products and specialized hospital medicines. We are actively expanding a portfolio spanning key therapeutic areas, such as dermatology, diabetology (human insulins), central nervous system (CNS), and anti-infective medicines.

We are the sole manufacturer of:

- natural penicillin
- erythromycin
- doxycycline
- rifampicin
 - a tuberculosis medicine

Key manufacturer of colistin – a medicine for sepsis

The sole manufacturer of dermatological aerosols

Key manufacturer of human insulins



Manufacturer of active pharmaceutical ingredients (APIs)



One in every five antibiotics administered in hospitals or prescribed by physicians is manufactured by TZF Polfa.



Anti-infective medicines

- Penicillins
- Macrolides
- Tetracyclines
- Advanced antibiotic formulations



Dermatology

- Topical antibiotics
- Antifungal agents
- Corticosteroid aerosols and gels



Central nervous system (CNS)

- Benzodiazepines (clonazepam, lorazepam)
- Therapies supporting neurological and psychiatric care



Diabetology

- Human insulins
- Modern oral antidiabetic medicines



Rheumatology / Highly potent products

- Immunosuppressive agents



Cardiovascular system

- Injectable medicines for hospital and intensive care settings



Probiotics and products supporting metabolic health



Dietary supplements and dermocosmetics



RESEARCH AND DEVELOPMENT (R&D) SERVICES

We provide comprehensive support at every stage of the project lifecycle: from formulation R&D and technology transfer to the preparation of regulatory dossiers.

We conduct both standard analyses and advanced projects involving active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs), including highly potent products.

- Preformulation studies
- Development and validation of analytical methods
- Analytical and microbiological testing
- Quality control and stability testing
- Industrial-scale technology transfer
- Registration support for medicinal products
- Studies of highly potent products up to OEB 5
- EU GMP-compliant laboratories





DEVELOPMENT AND MANUFACTURING CENTRE FOR HIGHLY POTENT DRUGS

TZF Polfa operates the most advanced facility in Central and Eastern Europe for the manufacture of highly potent injectable medicines.

Spanning 12,000 square metres, the site integrates Quality Control (QC) and stability-testing laboratories, an R&D department, packaging infrastructure supporting a wide range of formats, and dedicated storage zones for active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs).

The facility is built around two robotic production lines.



Multifunctional aseptic filling line for ampoules, pre-filled syringes and vials containing solutions, featuring lyophilization capabilities

Dedicated to sterile, highly potent drug production (**OEB 5**). Equipped with isolator technology and a fully automated production system, the line enables the safe manufacture of liquid and lyophilized injectable products. Annual throughput ranges from **6 to 10 million** units, depending on the product type and manufacturing process.

Multifunctional aseptic filling line for vials with solutions and powders, featuring lyophilization capabilities

Dedicated to sterile drug production, including highly potent products (**OEB 4**). This flexible system, equipped with isolator technology, automated process control and inspections, ensures high quality, process safety, and a capacity of up to **20 million** vials per year.



Scan the code
to watch the video



TZF POLFA WORLDWIDE

We understand the unique requirements of different markets and recognize that successful partnerships require flexibility – from licensing and distribution to direct sales and local representation.

Drawing on our experience, we can respond quickly to our partners' needs and provide solutions that are proven to work.



Scan the code
to learn more



CONTACT US

Contact us.

info@tzf.pl
emergencysupply@tzf.pl

phone +48 (22) 510 80 01

TZf Polfa

Tarchomińskie Zakłady Farmaceutyczne "Polfa" S.A.
ul. A. Fleminga 2, 03-176 Warsaw, Poland

NIP [Tax Identification Number] 5250000564 |
REGON [National Business Registry Number] 010721743 |
KRS [National Court Register] 27471

www.tzfpolfa.pl

TZF/474/12/009/2026